This is a phase II study (with targeted recruitment of 30 participants) designed to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-[18F]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard. Subjects consenting to study participation will receive the [18-F] CETO followed by the PET/CT scan.
Study Name: Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism
Status: Not yet recruiting
Conditions: Primary aldosteronism
Interventions: Biological: [18-F]CETO
Locations: University of Calgary, Calgary, Alberta, Canada
Study link: https://clinicaltrials.gov/ct2/show/NCT05472493
To search for other studies by topic, location, or status, go to our Clinical Studies page.